| Mechanisms and barriers in cancer nanomedicine: addressing challenges, looking for solutions TJ Anchordoquy, Y Barenholz, D Boraschi, M Chorny, P Decuzzi, ... ACS nano 11 (1), 12-18, 2017 | 310 | 2017 |
| Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin GH Petersen, SK Alzghari, W Chee, SS Sankari, NM La-Beck Journal of controlled release 232, 255-264, 2016 | 289 | 2016 |
| Immune checkpoint inhibitors: new insights and current place in cancer therapy NM La‐Beck, GW Jean, C Huynh, SK Alzghari, DB Lowe Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35 (10 …, 2015 | 246 | 2015 |
| New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy AA Gabizon, Y Patil, NM La-Beck Drug resistance updates 29, 90-106, 2016 | 238 | 2016 |
| Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients NM La-Beck, BA Zamboni, A Gabizon, H Schmeeda, M Amantea, ... Cancer chemotherapy and pharmacology 69, 43-50, 2012 | 108 | 2012 |
| Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: a minireview of current clinical guidelines S Trinh, A Le, S Gowani, NM La-Beck Asia-Pacific journal of oncology nursing 6 (2), 154-160, 2019 | 104 | 2019 |
| Nanoparticle interactions with the immune system: clinical implications for liposome-based cancer chemotherapy NM La-Beck, AA Gabizon Frontiers in immunology 8, 246294, 2017 | 88 | 2017 |
| Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology WP Caron, JC Lay, AM Fong, NM La-Beck, P Kumar, SE Newman, ... Journal of Pharmacology and Experimental Therapeutics 347 (3), 599-606, 2013 | 78 | 2013 |
| A Phenotype–Genotype Approach to Predicting CYP450 and P‐Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir JB Dumond, M Vourvahis, NL Rezk, KB Patterson, HC Tien, N White, ... Clinical Pharmacology & Therapeutics 87 (6), 735-742, 2010 | 77 | 2010 |
| Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate R Rajan, MK Sabnani, V Mavinkurve, H Shmeeda, H Mansouri, ... Journal of Controlled Release 271, 139-148, 2018 | 65 | 2018 |
| Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses MK Sabnani, R Rajan, B Rowland, V Mavinkurve, LM Wood, AA Gabizon, ... Nanomedicine: Nanotechnology, Biology and Medicine 11 (2), 259-262, 2015 | 57 | 2015 |
| Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients T Golan, T Grenader, P Ohana, Y Amitay, H Shmeeda, NM La‐Beck, ... Cancer medicine 4 (10), 1472-1483, 2015 | 56 | 2015 |
| The Role of Pegylated Liposomal Doxorubicin in Ovarian Cancer: A Meta‐Analysis of Randomized Clinical Trials JM Gibson, S Alzghari, C Ahn, H Trantham, NM La‐Beck The oncologist 18 (9), 1022-1031, 2013 | 53 | 2013 |
| Nanoparticle-induced complement activation: implications for cancer nanomedicine NM La-Beck, MR Islam, MM Markiewski Frontiers in immunology 11, 603039, 2021 | 45 | 2021 |
| Harnessing liposome interactions with the immune system for the next breakthrough in cancer drug delivery NM La-Beck, X Liu, LM Wood Frontiers in pharmacology 10, 439781, 2019 | 44 | 2019 |
| Translational considerations in nanomedicine: the oncology perspective AA Gabizon, RTM de Rosales, NM La-Beck Advanced Drug Delivery Reviews 158, 140-157, 2020 | 41 | 2020 |
| Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment NM La-Beck, X Liu, H Shmeeda, C Shudde, AA Gabizon Seminars in Cancer Biology 68, 175-185, 2021 | 36 | 2021 |
| Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context AD Le, SK Alzghari, GW Jean, NM La-Beck Therapeutics and Clinical Risk Management, 223-236, 2017 | 23 | 2017 |
| Quantifying autophagosomes and autolysosomes in cells using imaging flow cytometry R Rajan, M Karbowniczek, HR Pugsley, MK Sabnani, A Astrinidis, ... Cytometry Part A 87 (5), 451-458, 2015 | 21 | 2015 |
| Optimizing Patient Outcomes with PD‐1/PD‐L1 Immune Checkpoint Inhibitors for the First‐Line Treatment of Advanced Non–Small Cell Lung Cancer NM La‐Beck, DT Nguyen, AD Le, SK Alzghari, ST Trinh Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 40 (3 …, 2020 | 15 | 2020 |
Saeed AlzghariTexas Health ResourcesVerified email at texashealth.org
